Her work has supported numerous successful global filings, approvals, and other regulatory commitments across the US, EU, and Japan.Dr. David received his Ph.D. in Applied Mathematics, with a specialization in Statistics, at the State University of New York at Stony Brook.Dr. In addition to these disease areas, Cliff has in-depth experience in all stages of program advancement from discovery to launch in diverse disease areas including virology, oncology, immunology, cardiovascular and neuroscience. Bloomberg the Company & Its Products Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Terminal Demo Request Timothy McCormack He comes to us from Collegium Pharmaceutical, where he supported abuse deterrent opioid formulations. He has deep expertise with regard to orphan disease drug development, psychometric and functional scale validation and real-world evidence generation to support regulatory and reimbursement objectives. Donnie McGrath - Career stats, game logs, leaderboard appearances, awards, and achievements for international club and tournament play Senior Vice President, Clinical Operations Vice President, Chemistry, Research & Development Frost has a B.A.

Francine Healy All rights reserved. Executive Director CMC His experiences range across a number of therapeutic and functional areas including medical affairs, clinical development, medical information, and business development.

Lisa Kamen, MHA She spent two years as that organizations Clinical Operations Risk Based Monitoring Business Lead, managing protocol risk assessment discussions for all Phase 2-3 studies in the organization. Croop brings to Biohaven over 25 years of clinical drug development experience in a wide range of neuroscience programs. She has a proven track record of successfully managing complex and challenging drug development programs within set timelines and budgets.Cliff is a 27-year veteran of the Pharmaceutical industry with a broad drug development experience and a track record of optimizing organizations and capabilities. The agreement between Biohaven and Genpharm includes NURTEC ODT, approved in the The most common adverse reaction was nausea (2% in patients who received NURTEC ODT compared to 0.4% in patients who received placebo).

Dr. Jensen graduated from the University of Connecticut where he received his Doctor of Pharmacy and Master of Business Administration degrees.Kathryn has research experience in college and graduated Lehigh University with a B.S.

Cliff Bechtold, M.S. Stock has more than 20 years of experience developing biostatistical solutions for the pharmaceutical industry. Melissa Beiner, M.D. While working in Neuroscience Drug Discovery at Bristol-Myers Squibb, Mr. Gentile worked on the team that discovered a novel treatment for Non-24 Sleep-Wake Disorder. Mr. Gentile also functioned as the Finance Alliance Manager between BMS and Pfizer for the clinical development of Eliquis. Christine Lesczczynski Andrea comes to use from Bristol-Myers Squibb where she held Clinical Protocol Management roles of increasing responsibility in the Infectious Diseases and Oncology portfolios.

Javier Gonzalez Chief Medical Officer Her experience spans across multiple therapeutic areas including neuroscience, oncology, immunology, and immuno-oncology. Donnie McGrath, M.D., Chief of Corporate Strategy and Business Development, Biohaven Pharmaceuticals (PRNewsfoto/Biohaven Pharmaceuticals) … Clinical Trial Associate, Clinical Operations Shomari Hogan, MD Donnie McGrath, M.D., Chief of Corporate Strategy and Business Development . At BMS, he served as clinical lead for several small molecule and biologic compounds targeting rare disease indications. Hould has worked for more than 15 years in both industry and academia.

Dr. Conway received his doctoral training in the Laboratory of Psychopharmacology under the tutelage of Dr. Loy Lytle where he earned a Ph.D. in Neuroscience from the University of California Santa Barbara and was first to systematically characterize maturational changes in the development of nociceptive (pain) mechanisms.Mr. He completed his residency in internal medicine at St. Elizabeth’s Medical Center, and fellowship in Infectious Disease at Tufts-New England Medical Center, both in Boston.Dr.